Over the past decade or so, the nonalcoholic beverage aisle has gone from sparsely populated to entirely overwhelming.
Here are a few hop water brands to try: https://t.co/7cVLQRYkVG
Iran is under growing pressure as the US blockade starves the country of billions of dollars in oil revenue, writes @helloimserene https://t.co/5t3TD9mO0a
Banks are poised for big staff cuts as artificial intelligence becomes more prevalent; meanwhile, bank mergers pick up in Europe. https://t.co/yuyK0Fi2Eg
The U.S. approved arms sales worth close to $6.7 billion for Israel and $9 billion for Saudi Arabia, deals that come as the Middle East remains on edge with President Trump weighing military strikes on Iran. https://t.co/xLwJ1dRubs
Nigeria is targeting as much as $3 billion a year in carbon-market revenue after approving a framework that opens one of Africa’s largest economies to large-scale trading of emission allowances https://t.co/obyG3QmX8g
As we step into the new year, our focus is clear: strengthen foundations, build with integrity, and create lasting impact. At Iphamar, it’s people before profit, purpose before pressure, and sustainability over speed. Wishing all a purposeful year ahead.
Africa's economic growth hinges on creating one billion jobs by the end of the century. Where will it find them? Read the Big Take: https://t.co/5p5Tl0wEC0
📷️: Arlette Bashizi/Bloomberg
Nigeria’s bonds are leading emerging-market gains, supported by President Tinubu’s reforms, stronger government revenue, easing inflation, and a more stable currency https://t.co/u7BnjXLuII
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the US by 2030, it said, the latest big investment by a pharmaceutical company reacting to President Trump's tariff policy https://t.co/bzV5AZHU6I
Policymakers at the Central Bank of Nigeria are poised to leave borrowing costs unchanged at their third meeting of the year to gauge the durability of a recent slowdown in inflation. https://t.co/OzH9c4D4NQ
Merck is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reports https://t.co/M1uekdxh0f